|
1
|
Selvan JP, Uthaman B, Abushaban L and
Jebaraj R: Homozygous familial hypercholesterolemia with
generalized arterial disease. Medical principles and practice:
international journal of the Kuwait University. Health Sci Centre.
16:75–78. 2007.
|
|
2
|
Shi Z, Yuan B, Zhao D, Taylor AW, Lin J
and Watts GF: Familial hypercholesterolemia in China: Prevalence
and evidence of underdetection and undertreatment in a community
population. Int J Cardiol. 174:834–836. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cuchel M, Bruckert E, Ginsberg HN, Raal
FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps
OS, Steinhagen-Thiessen E, et al: Homozygous familial
hypercholesterolaemia: New insights and guidance for clinicians to
improve detection and clinical management. A position paper from
the Consensus Panel on Familial Hypercholesterolaemia of the
European Atherosclerosis Society. Turk Kardiyol Dern Ars. 43:1–4.
2015.(In Turkish). PubMed/NCBI
|
|
4
|
Page MM, Bell DA, Hooper AJ, Watts GF and
Burnett JR: Lipoprotein apheresis and new therapies for severe
familial hypercholesterolemia in adults and children. Best Pract
Res Clin Endocrinol Metab. 28:387–403. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vuorio A, Tikkanen MJ and Kovanen PT:
Inhibition of hepatic microsomal triglyceride transfer protein-a
novel therapeutic option for treatment of homozygous familial
hypercholesterolemia. Vasc Health Risk Manag. 10:263–270. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gidding SS: The complexities of homozygous
familial hypercholesterolemia management. Pediatr Transplant.
20:1020–1021. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
France M: Homozygous familial
hypercholesterolaemia: Update on management. Paediatr Int Child
Health. 36:243–247. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
France M, Rees A, Datta D, Thompson G,
Capps N, Ferns G, Ramaswami U, Seed M, Neely D, Cramb R, et al:
HEART UK statement on the management of homozygous familial
hypercholesterolaemia in the United Kingdom. Atherosclerosis.
255:128–139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao X, Bu L, Qin S, Kong D, Fan B and Ge
J: Early development of xanthoma and coronary disease in a young
female with homozygous familial hypercholesterolemia. Int J
Cardiol. 176:e15–e19. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang L, Gao F, Hu LB, Sun LY, Pan XD, Lin
J, Zhang HB, Yong Q, Wang Q, Yang Y, et al: Seven-year clinical
follow-up of a Chinese homozygous familial hypercholesterolemia
child with premature xanthomas and coronary artery disease-a need
for early diagnosis and aggressive treatment. Int J Cardiol.
177:188–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vallejo-Vaz AJ, Kondapally Seshasai SR,
Cole D, Hovingh GK, Kastelein JJ, Mata P, Raal FJ, Santos RD, Soran
H, Watts GF, et al: Familial hypercholesterolaemia: A global call
to arms. Atherosclerosis. 243:257–259. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Watts GF, Gidding S, Wierzbicki AS, Toth
PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston
M, et al: Integrated guidance on the care of familial
hypercholesterolaemia from the International FH Foundation. Eur J
Prev Cardiol. 22:849–854. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ito MK and Watts GF: Challenges in the
diagnosis and treatment of homozygous familial
hypercholesterolemia. Drugs. 75:1715–1724. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Besseling J, Sjouke B and Kastelein JJ:
Screening and treatment of familial hypercholesterolemia-Lessons
from the past and opportunities for the future (based on the
Anitschkow Lecture 2014). Atherosclerosis. 241:597–606. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cuchel M, Meagher EA, du Toit Theron H,
Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK,
Gaudet D, et al: Efficacy and safety of a microsomal triglyceride
transfer protein inhibitor in patients with homozygous familial
hypercholesterolaemia: A single-arm, open-label, phase 3 study.
Lancet. 381:40–46. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raal FJ, Honarpour N, Blom DJ, Hovingh GK,
Xu F, Scott R, Wasserman SM and Stein EA; TESLA Investigators, :
Inhibition of PCSK9 with evolocumab in homozygous familial
hypercholesterolaemia (TESLA Part B): A randomised, double-blind,
placebo-controlled trial. Lancet. 385:341–350. 2015. View Article : Google Scholar : PubMed/NCBI
|
